The use of Campath-1H as induction therapy in renal transplantation: Preliminary results

Gaetano Ciancio*, George W. Burke, Jeffrey J. Gaynor, Adela Mattiazzi, Ramin Roohipour, Manuel R. Carreno, David Roth, Phillip Ruiz, Warren Kupin, Anne Rosen, Violet Esquenazi, Andreas G. Tzakis, Joshua Miller

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

116 Scopus citations


Background. In an attempt to reduce both initial and long-term (nephrotoxic) calcineurin inhibitor maintenance dosage and totally eliminate maintenance corticosteroids, alemtuzumab (Campath-1H) was used as induction therapy in first cadaver and non-HLA-identical living donor renal transplantation. Methods. Forty-four de novo renal allograft recipients were treated with Campath-1H (0.3 mg/kg) on days 0 and 4 postoperatively, preceded by methylprednisolone boluses. Maintenance target 12-hr tacrolimus trough levels of 5 to 7 ng/mL were operational from the outset as well as (reduced) mycophenolate mofetil dosage of 500 mg twice daily. No corticosteroids were planned to be given after the first week postoperatively. Results. With a median follow-up of 9 (range, 1-19) months, patient and graft survival rates are each at 100%. Biopsy-proven acute rejection was diagnosed in four patients. Infections requiring hospitalization developed in four patients. Thirty-eight recipients remain without the need for long-term corticosteroid therapy. Conclusions. In an early assessment, the combination of Campath-1H, low dosing of tacrolimus and mycophenolate mofetil, and avoidance of maintenance corticosteroid use seems to be safe and effective for kidney transplant recipients. Long-term outcomes will be reported in the future.

Original languageEnglish (US)
Pages (from-to)426-433
Number of pages8
Issue number3
StatePublished - Aug 15 2004


  • Acute rejection
  • Campath-1H
  • Induction therapy
  • Mycophenolate mofetil
  • Renal allograft
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'The use of Campath-1H as induction therapy in renal transplantation: Preliminary results'. Together they form a unique fingerprint.

Cite this